Biogen Inc (NASDAQ: BIIB) has reported earnings for its first fiscal quarter (ending March 31) of $2.71 versus $2.69 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $8.05 compared to $21.62 a year ago.
Recent Price Action
On 4/24/24, Biogen Inc (NASDAQ: BIIB) stock enjoyed a large increase of 4.6%, closing at $201.99. Moreover, this advance was accompanied by exceptionally high trading volume at 257% of normal. Relative to the market the stock has been weak over the last nine months but has risen 3.5% during the last week.
Current PriceTarget Research Rating
BIIB is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Biogen has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Biogen has a neutral Appreciation Score of 58 but a poor Power Rating of 20, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment